rapid micro biosystems inc - RPID

RPID

Close Chg Chg %
3.07 0.00 0.00%

Open Market

3.07

0.00 (0.00%)

Volume: 167.79K

Last Updated:

Jan 13, 2026, 3:57 PM EDT

Company Overview: rapid micro biosystems inc - RPID

RPID Key Data

Open

$3.06

Day Range

2.92 - 3.10

52 Week Range

1.02 - 4.50

Market Cap

$136.07M

Shares Outstanding

44.32M

Public Float

23.65M

Beta

1.37

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

177.95K

 

RPID Performance

1 Week
 
-1.92%
 
1 Month
 
-15.66%
 
3 Months
 
-0.32%
 
1 Year
 
149.59%
 
5 Years
 
N/A
 

RPID Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About rapid micro biosystems inc - RPID

Rapid Micro Biosystems, Inc. is a life sciences technology company. It provides automated solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus on December 29, 2006 and is headquartered in Lexington, MA.

RPID At a Glance

Rapid Micro Biosystems, Inc.
25 Hartwell Avenue
Lexington, Massachusetts 02421
Phone 1-978-349-3200 Revenue 28.05M
Industry Industrial Machinery Net Income -46,889,000.00
Sector Producer Manufacturing 2024 Sales Growth 24.566%
Fiscal Year-end 12 / 2025 Employees 163
View SEC Filings

RPID Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.398
Price to Book Ratio 0.514
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.115
Enterprise Value to Sales -0.191
Total Debt to Enterprise Value -1.154

RPID Efficiency

Revenue/Employee 172,092.025
Income Per Employee -287,662.577
Receivables Turnover 3.728
Total Asset Turnover 0.232

RPID Liquidity

Current Ratio 4.607
Quick Ratio 3.457
Cash Ratio 2.888

RPID Profitability

Gross Margin -0.389
Operating Margin -177.958
Pretax Margin -167.078
Net Margin -167.156
Return on Assets -38.812
Return on Equity -48.504
Return on Total Capital -57.518
Return on Invested Capital -45.855

RPID Capital Structure

Total Debt to Total Equity 8.186
Total Debt to Total Capital 7.566
Total Debt to Total Assets 6.283
Long-Term Debt to Equity 6.574
Long-Term Debt to Total Capital 6.077
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rapid Micro Biosystems Inc - RPID

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
23.23M 17.13M 22.52M 28.05M
Sales Growth
+44.50% -26.25% +31.44% +24.57%
Cost of Goods Sold (COGS) incl D&A
30.97M 25.67M 28.00M 28.16M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.63M 3.98M 3.10M 3.36M
Depreciation
1.53M 3.68M 2.81M 2.96M
Amortization of Intangibles
100.00K 300.00K 300.00K 400.00K
COGS Growth
+28.26% -17.11% +9.08% +0.56%
Gross Income
(7.74M) (8.54M) (5.49M) (109.00K)
Gross Income Growth
+4.09% -10.32% +35.77% +98.01%
Gross Profit Margin
-33.32% -49.85% -24.36% -0.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
39.49M 54.68M 51.08M 49.81M
Research & Development
9.78M 12.87M 12.82M 14.60M
Other SG&A
29.71M 41.81M 38.26M 35.21M
SGA Growth
+75.76% +38.46% -6.59% -2.48%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 22.74M
-
EBIT after Unusual Expense
(69.97M) (63.22M) (56.56M) (49.92M)
Non Operating Income/Expense
(808.00K) 1.84M 4.13M 3.05M
Non-Operating Interest Income
- 1.78M 4.21M 3.16M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 2.65M
-
Interest Expense Growth
- - - -23.12%
-
Gross Interest Expense
- - - 2.65M
-
Interest Capitalized
- - - -
-
Pretax Income
(73.43M) (61.38M) (52.44M) (46.87M)
Pretax Income Growth
-98.77% +16.41% +14.57% +10.62%
Pretax Margin
-316.09% -358.27% -232.85% -167.08%
Income Tax
91.00K (576.00K) 31.00K 22.00K
Income Tax - Current - Domestic
(20.02M) 16.17M 12.42M 11.49M
Income Tax - Current - Foreign
91.00K (576.00K) 31.00K 22.00K
Income Tax - Deferred - Domestic
20.02M (16.17M) (12.42M) (11.49M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(73.52M) (60.81M) (52.47M) (46.89M)
Minority Interest Expense
- - - -
-
Net Income
(73.52M) (60.81M) (52.47M) (46.89M)
Net Income Growth
-98.30% +17.30% +13.71% +10.63%
Net Margin Growth
-316.48% -354.91% -232.99% -167.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(73.52M) (60.81M) (52.47M) (46.89M)
Preferred Dividends
- - - 4.51M
-
Net Income Available to Common
(78.03M) (60.81M) (52.47M) (46.89M)
EPS (Basic)
-1.8818 -1.4323 -1.2195 -1.076
EPS (Basic) Growth
-60.92% +23.89% +14.86% +11.77%
Basic Shares Outstanding
41.47M 42.45M 43.02M 43.58M
EPS (Diluted)
-1.8818 -1.4323 -1.2195 -1.076
EPS (Diluted) Growth
-60.92% +23.89% +14.86% +11.77%
Diluted Shares Outstanding
41.47M 42.45M 43.02M 43.58M
EBITDA
(45.60M) (59.24M) (53.46M) (46.56M)
EBITDA Growth
-57.04% -29.90% +9.76% +12.91%
EBITDA Margin
-196.29% -345.76% -237.39% -165.97%

Snapshot

Average Recommendation BUY Average Target Price 8.00
Number of Ratings 4 Current Quarters Estimate -0.21
FY Report Date 03 / 2026 Current Year's Estimate -0.858
Last Quarter’s Earnings -0.225 Median PE on CY Estimate N/A
Year Ago Earnings -0.995 Next Fiscal Year Estimate -0.69
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 4 1
Mean Estimate -0.21 -0.20 -0.86 -0.69
High Estimates -0.21 -0.20 -0.81 -0.69
Low Estimate -0.21 -0.20 -0.91 -0.69
Coefficient of Variance N/A N/A -5.82 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Rapid Micro Biosystems Inc - RPID

Date Name Shares Transaction Value
Mar 12, 2025 Sean M. Wirtjes CHIEF FINANCIAL OFFICER 489,955 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.39 per share 1,170,992.45
Mar 12, 2025 Robert Spignesi PRESIDENT AND CEO; Director 872,366 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.39 per share 2,084,954.74
Mar 12, 2025 John Wilson CHIEF OPERATING OFFICER 232,474 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.39 per share 555,612.86
Feb 21, 2025 Sean M. Wirtjes CHIEF FINANCIAL OFFICER 121,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Robert Spignesi PRESIDENT AND CEO; Director 290,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 John Wilson CHIEF OPERATING OFFICER 89,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rapid Micro Biosystems Inc in the News